- Home
- PRZO vs NXL Comparison
PRZO vs NXL Comparison
Compare PRZO & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRZO
- NXL
- Stock Information
- Founded
- PRZO 2014
- NXL 2010
- Country
- PRZO Israel
- NXL United States
- Employees
- PRZO N/A
- NXL N/A
- Industry
- PRZO
- NXL Medical Specialities
- Sector
- PRZO
- NXL Health Care
- Exchange
- PRZO Nasdaq
- NXL Nasdaq
- Market Cap
- PRZO 20.1M
- NXL 21.0M
- IPO Year
- PRZO 2023
- NXL 2022
- Fundamental
- Price
- PRZO $1.90
- NXL $1.12
- Analyst Decision
- PRZO
- NXL Strong Buy
- Analyst Count
- PRZO 0
- NXL 1
- Target Price
- PRZO N/A
- NXL $5.00
- AVG Volume (30 Days)
- PRZO 1.8M
- NXL 116.3K
- Earning Date
- PRZO 09-02-2025
- NXL 08-07-2025
- Dividend Yield
- PRZO N/A
- NXL N/A
- EPS Growth
- PRZO N/A
- NXL N/A
- EPS
- PRZO N/A
- NXL N/A
- Revenue
- PRZO $932,154.00
- NXL $131,065.00
- Revenue This Year
- PRZO N/A
- NXL $79.59
- Revenue Next Year
- PRZO N/A
- NXL $334.65
- P/E Ratio
- PRZO N/A
- NXL N/A
- Revenue Growth
- PRZO 50.22
- NXL N/A
- 52 Week Low
- PRZO $0.49
- NXL $0.59
- 52 Week High
- PRZO $3.16
- NXL $4.49
- Technical
- Relative Strength Index (RSI)
- PRZO 77.30
- NXL 54.25
- Support Level
- PRZO $1.52
- NXL $0.97
- Resistance Level
- PRZO $1.80
- NXL $1.08
- Average True Range (ATR)
- PRZO 0.12
- NXL 0.08
- MACD
- PRZO 0.05
- NXL 0.03
- Stochastic Oscillator
- PRZO 98.33
- NXL 70.00
About PRZO ParaZero Technologies Ltd.
ParaZero Technologies Ltd is an aerospace company that is focused on drone safety systems and engaged in the business of designing, developing, and providing autonomous parachute safety systems for commercial drones, also known as unmanned aerial systems. The ParaZero SafeAir system of the company applies real-time data analytics to identify and mitigate flight risks autonomously and increase safety for bystanders while protecting the loss of expensive drones, equipment, and payloads.
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.